Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. 27 November 2020. Agam Sharda.

Executive Summary

The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.

“If you can give a high enough [radiation] dose to a tumor, you could kill it. The problem is the side effects and the rest of the body that cannot handle all this dose – you can kill the cancer, but you kill a whole lot of other stuff as well. The fact that Flash can help to preserve healthy tissue or to reduce side effects by up to 50% [is] really exciting, because you can now start to think about giving more dose to a cancer without having to damage healthy tissue.” – Agum Sharda, senior director of Flash, Varian

Click here for a free trial of Medtech Insight

Related Content

Topics

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel